WMS 2023 poster: Age at loss of ambulation in patients with DMD from the STRIDE Registry and the CINRG Natural History Study: A matched cohort analysis
This poster, presented at WMS 2023, explores the effect of ataluren and standard of care (SoC) receival on age at loss of ambulation in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) vs SoC alone
Explore the demographics of patients in the STRIDE Registry and CINRG Natural History Study
Compare the effectiveness of ataluren and SoC in delaying loss of ambulation across the different patient groups
Learn more about the use of ataluren in patients with this rare disease
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This poster was developed and funded by PTC Therapeutics for WMS 2023.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300184 | January 2024
Sign in or register to access exclusive content on this site